Respiratory diseases among U.S. military personnel: countering emerging threats.
G C Gray, J D Callahan, A W Hawksworth...
https://pubmed.ncbi.nlm.nih.gov/10341174/Actively Recruiting
Led by Henry M. Jackson Foundation for the Advancement of Military Medicine · Updated on 2026-11-02
54
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the immune responses and side effects of FDA-approved vaccines for COVID-19 and influenza in the Comparative Immunogenicity of Respiratory Virus Vaccines CIRV2 study. This Phase IV trial focuses on adults aged 18 to 79 who have certain risk factors for severe COVID-19 but do not have severe immune system impairments. In 2026, the study compares two COVID-19 vaccines the Novavax recombinant vaccine and the Pfizer-BioNTech mRNA vaccine. Participants will be randomly assigned to receive either the Pfizer-BioNTech mRNA COVID-19 vaccine or the Novavax recombinant protein vaccine. The study involves vaccination followed by blood sample collections to measure immune responses before vaccination, 30 days after, and 150 days after vaccination in the second year, with the first year including assessments before vaccination and 30 days after. This allows researchers to track the bodys antibody levels and neutralizing antibody activity over time. During the study, participants will attend clinic visits around 30 days and 150 days post-vaccination and complete online follow-ups for up to 9 months. Blood samples will be analyzed to assess IgG binding antibody levels and neutralizing antibody titers. The study team monitors participants for vaccine reactions and immune responses to better understand differences between the vaccines. Total participation lasts around one year, with ongoing assessments to evaluate vaccine effectiveness and safety.
CONDITIONS
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
M
Marianne Spevak, BSHS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Henry M. Jackson Foundation for the Advancement of Military Medicine
Lead Sponsor
Centers for Disease Control and Prevention
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Pfizer‑BioNTech mRNA vaccine | Novavax protein vaccine | Current product‑matched updated vaccine |
|---|---|---|---|
| What it is | An mRNA COVID‑19 vaccine evaluated for immune response in adults. | A recombinant protein‑based COVID‑19 vaccine evaluated for immune response in adults. | A seasonally updated COVID‑19 vaccine targeting current variants, recommended for adults. |
| Role in trial | One of two randomized active vaccine arms. | One of two randomized active vaccine arms. | Represents typical seasonal COVID‑19 vaccine outside of trial conditions. |
| Primary use | Stimulate immune response against COVID‑19 as mRNA booster. | Stimulate immune response against COVID‑19 as protein booster. | Seasonal COVID‑19 vaccine booster matched to circulating strains. |
| Administration | Given per trial schedule, booster dose as mRNA injection. | Given per trial schedule, booster dose as protein vaccine injection. | Administered as updated seasonal COVID‑19 vaccine booster (details per annual recommendations). |
| Broader evidence | mRNA COVID‑19 boosters have demonstrated strong immune responses in previous studies. | Protein‑based boosters have shown immune activity comparable to mRNA boosters in earlier studies. | Received current‑season recommendation based on review of variant‑matched vaccine efficacy data. |
| Limitations | Immunogenicity results may not predict protection against future variants. | Immunogenicity measures may not reflect variant‑matched effectiveness outside trial. | Recommendations may change if circulating variants evolve unexpectedly. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 1 year
Participants receive either the Pfizer-BioNTech mRNA COVID-19 vaccine or the Novavax recombinant protein vaccine. Blood samples are collected before vaccination, around 30 days, and 150 days after vaccination. Participants also complete online follow-ups for up to 9 months.
3 clinic visits and ongoing online follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
G C Gray, J D Callahan, A W Hawksworth...
https://pubmed.ncbi.nlm.nih.gov/10341174/Anthony M Marchese, Matthew Rousculp, John Macbeth...
https://pubmed.ncbi.nlm.nih.gov/37992183/Ivan Chun Hang Lam, Ran Zhang, Kenneth Keng Cheung Man...
https://pubmed.ncbi.nlm.nih.gov/38403654/Eric D Laing, Carol D Weiss, Emily C Samuels...
https://pubmed.ncbi.nlm.nih.gov/35203111/Ann I Scher, Catherine M Berjohn, Celia Byrne...
https://pubmed.ncbi.nlm.nih.gov/35899278/Adam T Biggs, Lanny F Littlejohn
https://pubmed.ncbi.nlm.nih.gov/35584186/Luke E Mease, Aaron M Smith
https://pubmed.ncbi.nlm.nih.gov/34854661/Wei Wang, Sabrina Lusvarghi, Rahul Subramanian...
https://pubmed.ncbi.nlm.nih.gov/36356586/Stephanie A Richard, Ann I Scher, Jennifer Rusiecki...
https://pubmed.ncbi.nlm.nih.gov/38130596/Henry M. Jackson Foundation for the Advancement of Military Medicine
Lead Sponsor
Centers for Disease Control and Prevention
Collaborating Sponsor